{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:27:34Z","timestamp":1762507654989},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10620-019-5473-5","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T12:38:41Z","timestamp":1549543121000},"page":"1599-1603","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Off-Label Teduglutide Therapy in Non-intestinal Failure Patients with Chronic Malabsorption"],"prefix":"10.1007","volume":"64","author":[{"given":"Alvin T.","family":"George","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betty H.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"5473_CR1","doi-asserted-by":"publisher","first-page":"7911","DOI":"10.1073\/pnas.93.15.7911","volume":"93","author":"DJ Drucker","year":"1996","unstructured":"Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA. 1996;93:7911\u20137916.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5473_CR2","first-page":"E1050","volume":"272","author":"PL Brubaker","year":"1997","unstructured":"Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol. 1997;272:E1050\u2013E1058.","journal-title":"Am J Physiol"},{"key":"5473_CR3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1053\/gast.2001.22555","volume":"120","author":"PB Jeppesen","year":"2001","unstructured":"Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120:806\u2013815.","journal-title":"Gastroenterology"},{"key":"5473_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1053\/j.gastro.2006.05.055","volume":"131","author":"PE Dube","year":"2006","unstructured":"Dube PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology. 2006;131:589\u2013605.","journal-title":"Gastroenterology"},{"key":"5473_CR5","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2009.05.057","volume":"137","author":"B Yusta","year":"2009","unstructured":"Yusta B, Holland D, Koehler JA, et al. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology. 2009;137:986\u2013996.","journal-title":"Gastroenterology"},{"key":"5473_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/00365520802538195","volume":"44","author":"L Bremholm","year":"2009","unstructured":"Bremholm L, Hornum M, Henriksen BM, Larsen S, Holst JJ. Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol. 2009;44:314\u2013319.","journal-title":"Scand J Gastroenterol"},{"key":"5473_CR7","doi-asserted-by":"publisher","first-page":"G211","DOI":"10.1152\/ajpgi.00530.2006","volume":"293","author":"DL Sigalet","year":"2007","unstructured":"Sigalet DL, Wallace LE, Holst JJ, et al. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol. 2007;293:G211\u2013G221.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"5473_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/014860710502900297","volume":"29","author":"A Perez","year":"2005","unstructured":"Perez A, Duxbury M, Rocha FG, et al. Glucagon-like peptide 2 is an endogenous mediator of postresection intestinal adaptation. JPEN J Parenter Enter Nutr. 2005;29:97\u2013101.","journal-title":"JPEN J Parenter Enter Nutr"},{"key":"5473_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11894-016-0511-3","volume":"18","author":"R Carroll","year":"2016","unstructured":"Carroll R, Benedetti E, Schowalter J, Buchman A. Management and complications of short bowel syndrome: an updated review. Curr Gastroenterol Rep. 2016;18:1\u201313.","journal-title":"Curr Gastroenterol Rep"},{"key":"5473_CR10","doi-asserted-by":"publisher","first-page":"1481.e3","DOI":"10.1053\/j.gastro.2012.09.007","volume":"143","author":"PB Jeppesen","year":"2012","unstructured":"Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143:1481.e3.","journal-title":"Gastroenterology"},{"key":"5473_CR11","first-page":"520","volume":"33","author":"DL Seidner","year":"2018","unstructured":"Seidner DL, Fujioka K, Boullata JI, Iyer K, Lee HM, Ziegler TR. Reduction of parenteral nutrition and hydration support and safety with long-term teduglutide treatment in patients with short bowel syndrome-associated intestinal failure: STEPS-3 study. Nutr Clin Pract Off Publ Am Soc Parent Enter Nutr. 2018;33:520\u2013527.","journal-title":"Nutr Clin Pract Off Publ Am Soc Parent Enter Nutr"},{"key":"5473_CR12","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1038\/ctg.2015.69","volume":"7","author":"LK Schwartz","year":"2016","unstructured":"Schwartz LK, O\u2019Keefe SJ, Fujioka K, et al. Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin Transl Gastroenterol. 2016;7:e142.","journal-title":"Clin Transl Gastroenterol"},{"key":"5473_CR13","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1136\/gut.2010.218271","volume":"60","author":"PB Jeppesen","year":"2011","unstructured":"Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O\u2019Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and\/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60:902\u2013914.","journal-title":"Gut"},{"key":"5473_CR14","first-page":"815-23.e1-3","volume":"11","author":"SJ O\u2019Keefe","year":"2013","unstructured":"O\u2019Keefe SJ, Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B. Safety and efficacy of teduglutide after 52\u00a0weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11:815-23.e1-3.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"5473_CR15","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/ibd.21117","volume":"16","author":"AL Buchman","year":"2010","unstructured":"Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn\u2019s disease. Inflamm Bowel Dis. 2010;16:962\u2013973.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-5473-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-019-5473-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-5473-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:14:57Z","timestamp":1581034497000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-019-5473-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5473"],"URL":"https:\/\/doi.org\/10.1007\/s10620-019-5473-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]},"assertion":[{"value":"22 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors have contributed substantially to this report and have approved its final version. No authors disclose a conflict of interest with regard to what is presented in this series.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}